Translational Mouse Models to Accelerate Neurodegenerative Disease Therapeutics

There is a tantalizing opportunity to advance the field of neurodegenerative diseases by developing animal models that accurately recapitulate key features of human pathology. In parallel, the identification and validation of translational biomarkers that help bridge the gap between preclinical studies and clinical trials can accelerate efforts to develop effective treatments and therapies. That’s why Biospective has developed and extensively characterized innovative mouse models with neuropathology induced by misfolded proteins, including amyloid-beta, tau, alpha-synuclein, and TDP-43 models.

In this GEN webinar, Biospective CEO & CSO Barry Bedell, MD, PhD, will discuss the multi-modality characterization of mouse models tailored for the preclinical evaluation of experimental therapeutic agents for neurodegenerative diseases including Alzheimer’s disease, tauopathies, Parkinson’s disease, and Amyotrophic Lateral Sclerosis (ALS). He will provide an overview of motor, behavioral, in vivo imaging, and quantitative immunohistochemistry/multiplex immunofluorescence data collected from various models, including adeno-associated virus (AAV) vector-induced, preformed fibril (PFF)-induced, and transgenic models. 

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.